ADHD Management and Neurocognitive Testing
At Peak Mental Health NW we are able to perform neurocognitive testing using an FDA-cleared tool that measures the 3 core domaines of ADHD: hyperactivity, impulsivity, and inattention.
1
What is QbTest Telehealth powered by QbCheck?
QbTest Telehealth is an FDA-cleared test measuring all three core symptom domains; hyperactivity, impulsivity, and inattention. It is used when evaluating ADHD symptoms and measuring response to ADHD treatment. This remote version (QbCheck) involves a 20-minute computer-based task that measures your ability to maintain attention and impulse control. Meanwhile, a camera tracks movements, and therefore activity, during the test. The results are based on a comparison of your performance with data from other people of the same sex and age.
2
Why test for ADHD?
Adding objective ADHD technology can assist to improve diagnosis accuracy, shorten the time to diagnosis, and capture treatment response. Testing is utilize to help guide medication management and make tailored recommendation based on your needs that are supported by evidence.
3
What do results look like?
Below is an example of a client test on the left and a data sample of individuals of the same age and assigned gender at birth. After you test, your results will be directly sent to your provider. At your follow up visit, the provider will explain your results.
References:
Hollis, C., Hall, C. L., Guo, B., James, M., Boadu, J., Groom, M. J., Brown, N., Kaylor‐Hughes, C., Moldavsky, M., Valentine, A. Z., Walker, G. M., Daley, D., Sayal, K., Morriss, R., the AQUA Trial Group, Curran, S., Clarke, J., Holsgrove, S., Jennings, T., … Williams, A. (2018). The impact of a computerised test of attention and activity (QbTest) on diagnostic decision‐making in children and young people with suspected attention deficit hyperactivity disorder: Single‐blind randomised controlled trial.
https://onlinelibrary.wiley.com/doi/10.1111/jcpp.12921 2. Martin-Key NA, Stevenson A, Roy P. Investigating the Clinical Utility of the Combined Use of Objective and Subjective Measures of ADHD During Treatment Optimization. J Clin Psychopharmacol. 2022 Mar-Apr 01;42(2):146-153. doi: 10.1097/JCP.0000000000001350. PMID: 33605643; PMCID: PMC8884177.